Jonathan Norris is a managing director for business development in SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations.

In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than nineteen years of banking experience working with healthcare companies and venture capital firms.

Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

Angelica is a scientist-in-residence at Civilization Ventures and earned her PhD in biophysics at Stanford University focusing on single-molecule imaging, bioengineering, computational structural biology, and biotechnology translation. Angelica is currently at Nurix Therapeutics where she develops tools to accelerate discovery of small molecules that degrade disease-causing proteins. Angelica is a National Science Foundation Fellow, a Stanford MedicineX ePatient Scholar and served on the leadership team of the Stanford Biotechnology Group. She received her BS in Biochemistry from UCLA.

Ash Khanna, PhD, MBA joined Pivotal in 2017.  Ash brings 20 years of experience in the venture capital, pharmaceutical and biotech arena. Most recently, he co-founded Vaxcyte (formerly Sutrovax), a Pivotal bioVentures portfolio company, where he served as Chief Business Officer.  Previously he was President & Chief Business Officer of Imagen Biotech, a VC-backed startup developing treatments for severe ophthalmic diseases.

Prior to his operating roles, Ash was a Principal at SV Life Sciences (SVLS), a healthcare focused venture capital firm, where he led and managed investments in many biotech and diagnostic companies including, among others, Ophthotech, Mpex Pharmaceuticals, Good Start Genetics and Itero Biopharmaceuticals.  He started his career in the pharmaceutical industry at Bristol-Myers Squibb where he held various positions including Team Leader responsible for the clinical advancement of multiple Diabetes programs including the currently marketed products, Onglyza® (Dipeptidyl peptidase-4 inhibitor) and Farxiga® (SGLT2 inhibitor).  Ash is a co-inventor on the Onglyza® patent.

Ash has an MBA from The Wharton School and a PhD in Pharmaceutics from SUNY-Buffalo.  He is also a Kauffman Fellow and initially trained as a pharmacist.

Mary is Founding Managing Director of BioRock Ventures, a Silicon Valley based life sciences venture fund investing in startups developing novel drugs to treat diseases. Mary has over 20 years of experience in biotech companies of all sizes at the C-level and in various M&A deal lead, licensing and strategy roles at Johnson & Johnson, Forest (now Allergan/Abbvie), and as a startup Founder. She has served as CBO and advisor for several dozen early stage ventures as well. Dr. Wheeler earned an MBA from MIT Sloan, a PhD from Princeton and a BA from Yale. She is a Kauffman Fellow Class 18.

Peyton Greenside is the CSO and co-founder of BigHat Biosciences. A pioneer of deep learning applied to life science problems, Peyton has developed computational, statistical, and AI/ML techniques to model, understand, and optimize biological sequences in academia and industry. Peyton was an inaugural Schmidt Science Fellow, a computational biologist at the Broad Institute, a scientific founder of Valis, and holds a PhD from Stanford University, an MPhil in Computational Biology from University of Cambridge, and a BA in Applied Math from Harvard.

Shahram is Founder and General Partner of Civilization Ventures, a venture capital firm focused on supporting founders in health tech and biology with a portfolio of over 25 companies. Shahram is also a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class therapeutics for cancer now in Phase 2 human clinical trials. Prior to Rgenix, he was founding CFO and VP of Corporate Development at NextBio, a genomics big data analytics pioneer acquired by Illumina.